Efficacy and Safety of Dioxidin Versus Miramistin in Superficial Pyoderma

Exclusion Criteria

• •1. Hypersensitivity to the active and/or excipients of the studied drugs.
• •2. Presence of signs of acute respiratory infections.
• •3. Deep pyoderma (furunculus, carbuncle, abscess, hydradenitis, etc.).
• •4. Use of local and systemic antibacterials, antiseptics, glucocorticosteroids, and antifungal agents less than 14 days prior to the screening visit.
• •5. Presence of infectious diseases requiring topical and/or systemic antibacterial therapy.
• •6. Vaccination of the patient less than 1 week prior to the screening visit.
• •7. Adrenal insufficiency.
• •8. Body temperature \>37C.
• •9. Fungal, viral skin infections, severe generalized bacterial skin lesions, other skin diseases.
• •10. Immunodeficiency states.
• •11. Positive HIV, Hepatitis B and C, or syphilis, or SARS-CoV-2 rapid test (COVID-19)
• •12. Presence of at least one of the following epidemiologic indicators: Return from foreign travel 7 days prior to screening; Close contact in the last 7 days prior to screening with an individual under observation for COVID-19 who subsequently became ill; Close contact in the last 7 days prior to screening with an individual with a laboratory confirmed diagnosis of COVID-19; Professional contacts in the last 7 days prior to screening with individuals who have a suspected or confirmed case of COVID-19.
• •13. Scalp lesion (where treatment procedures and effectiveness cannot be adequately evaluated due to thick/long hair).
• •14. Allergic reactions to antibacterial drugs, antiseptic drugs in history.
• •15. Diabetes mellitus type 1 or 2.
• •16. Any other comorbidities or conditions that, in the opinion of the investigator, make it difficult to interpret treatment results or make it impossible to perform procedures in this clinical trial or pose a risk to the patient when participating in the study (e.g., a history of severe allergies, atopic dermatitis in case the affected area overlaps with the area of pyoderma).
• •17. History of malignancy, with the exception of patients who have not had the disease in the past 5 years, patients with fully cured basal cell carcinoma of the skin, or fully cured carcinoma in situ.
• •18. Severe, decompensated, or unstable somatic diseases (any disease or condition that is life-threatening or worsens the patient's prognosis, or makes it impossible for the patient to participate in a clinical trial).
• •19. The need for concomitant therapy with any of the drugs listed as "Prohibited Concomitant Treatment".
• •20. History of alcohol and/or drug dependence.
• •21. Participation in another clinical trial less than 3 months prior to the Screening Visit.
• •22. Pregnancy.
• •23. Breastfeeding period.
• •Withdrawal Criteria:
• •1. Withdrawal of Informed Consent by the patient.